In preclinical studies, an ADAPT labelled with 99mTc ([99mTc]Tc-ADAPT6) demonstrated efficient differentiation of HER2-positive and HER2-negative tumours, and low uptake in tissues, which frequently harbour breast cancer metastases [20,21]. Here, ERBB2 is linked to neoplasm.